Nxstage Medical Beats Up on Analysts Yet Again

Before you go, we thought you'd like these...
Before you go close icon

Nxstage Medical (NAS: NXTM) reported earnings on May 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Nxstage Medical met expectations on revenues and exceeded expectations on earnings per share.

Compared with the prior-year quarter, revenue improved and GAAP loss per share shrank.


Margins improved across the board.

Revenue details
Nxstage Medical booked revenue of $57.0 million. The 11 analysts polled by S&P Capital IQ wanted to see revenue of $56.4 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $50.6 million.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.09. The 10 earnings estimates compiled by S&P Capital IQ averaged -$0.10 per share. GAAP EPS were -$0.09 for Q1 compared to -$0.11 per share for the prior-year quarter.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 37.4%, 170 basis points better than the prior-year quarter. Operating margin was -6.4%, 280 basis points better than the prior-year quarter. Net margin was -9.0%, 290 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $58.8 million. On the bottom line, the average EPS estimate is -$0.09.

Next year's average estimate for revenue is $241.6 million. The average EPS estimate is -$0.26.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 142 members out of 174 rating the stock outperform, and 32 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Nxstage Medical a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $26.00.

Over the decades, small-cap stocks like Nxstage Medical have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.

At the time this article was published

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners